财通证券指出，haohai biotec (06826) fell more than 8% after the performance announcement, dropping 8.41% to HK$31.05 as of the press time, with a turnover of 8.256 million Hong Kong dollars.
According to the Financial Channel APP, haohai biotec (06826) fell more than 8% after the performance announcement, dropping 8.41% to HK$31.05 as of the press time, with a turnover of 8.256 million Hong Kong dollars.
On the news front, haohai biotec announced that in the first three quarters of 2024, the revenue was 2.075 billion yuan (RMB, the same below), a year-on-year increase of 4.69%; the net profit attributable to shareholders of the listed company was 0.341 billion yuan, a year-on-year increase of 4.31%; the basic earnings per share were 1.46 yuan. Sinolink Securities issued a research report stating that the company's performance in the third quarter was below expectations; the net profit attributable to the mother in the third quarter was 0.106 billion yuan, compared to 0.122 billion yuan in the third quarter of 2023, a year-on-year decrease of 13.13%, mainly due to the price reduction factor of ophthalmology group procurement and a research and development investment of 0.063 billion yuan in the third quarter, a year-on-year increase of 18.9%.
Caitong Securities pointed out that both gross margin and net margin of the company are under pressure, with continuous increase in research and development investment; the gross margin in 1-3Q24 fell by 1.2 percentage points to 70.4%, and the net margin fell by 1.3 percentage points to 15.2%. Looking at the expense side, the sales management/research and development expense ratios were 28.7%/15.7%/9.1%, respectively, -2.9/-0.1/+1.3 percentage points. The company pays attention to research and development investment, and the research and development expense ratio in 1-3Q24 has significantly increased.
